Position: Junior Research Group Leader "Translational Radioimmunotherapy"

Department: DKTK Dresden

Code number: 2020-0228

The German Cancer Research Center is the largest biomedical research institution in Germany. With more than 3,000 employees, we operate an extensive scientific program in the field of cancer research.

The German Cancer Consortium (DKTK) is a joint initiative of the German Ministry for Education and Research (BMBF), the contributing federal states, the German Cancer Aid (Deutsche Krebshilfe), and the DKFZ. The alliance between the DKFZ in Heidelberg as the core center and the partner sites at the University Hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, München and Tübingen as well as the National Center for Tumor Diseases in Heidelberg and Dresden allows access and co-operation in many areas of translational cancer research. The main focus of DKTK is placed on interdisciplinary research projects and innovative translational and early clinical trials that aim to improve prevention and diagnosis of cancer, and to accelerate the implementation of personalized therapies in cancer patients.

 

Job description:

We seek to appoint a junior group leader with a strong background in the field of translational research in immunotherapy of cancer, preferentially including radio-immunotherapeutic approaches. Competitive applicants are expected to use state-of-the-art pre-clinical models and should have an exceptional track record of accomplishment, with evident future potential and commitment to translational/applied cancer research. The group is thought to be situated in a preclinical-translational area, i.e. should use in vivo models for combined radio- and immunotherapy and co-operate with clinical researchers for the design of future clinical trials.

The DKTK partner site Dresden and the DKFZ provide access to first class state-of-the-art core facilities in Dresden and Heidelberg. Translational research activities are supported by access to large patient cohorts, high quality tumor tissue banks and excellent clinical research facilities.

The junior research group will be located at OncoRay and Medical Oncology of the University Hospital Dresden and the Technische Universität Dresden, as well as with other research groups of the DKTK and the DKFZ.

Requirements:

Candidates must hold a Ph.D. or M.D. degree and have an internationally competitive publication record. Applications of medical scientists as well as clinician scientists are welcome. Applications should include CV, list of publications and a 3-4 page research synopsis that both summarizes current/past research accomplishments and outlines of the candidate´s research program for the next 5 years. 

The successful candidate should be able to raise financial support from national and international third-party funds.

We offer:

  • Interesting, versatile workplace
  • International, attractive working environment
  • Campus with modern state-of-the-art infrastructure
  • Salary according to TV-L including social benefits
  • Possibility to work part-time
  • Flexible working hours
  • Comprehensive further training program

Earliest Possible Start Date: 01.01.2021

Duration: The position is limited up to 5 years.

The position can in principle be part-time.

Application Deadline: 13.10.2020

Contact:

Prof. Dr. Mechthild Krause
Phone +49 (0)351 458 5292

Please note that we do not accept applications submitted via email.


The German Cancer Research Center is committed to increase the percentage of female scientists and encourages female applicants to apply. Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.                           

To apply for a position please use our online application portal (www.dkfz.de/jobs).

We ask for your understanding that we cannot return application documents that are sent to us by post (Deutsches Krebsforschungszentrum, Personalabteilung, Im Neuenheimer Feld 280, 69120 Heidelberg) and that we do not accept applications submitted via email. We apologize for any inconvenience this may cause.